64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile ...

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...

Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved ...

Of 38 efficacy-evaluable patients, the overall (cumulative) major molecular response (MMR) rate was 74% (28/38) by 24 weeks, with 64% (18/28) achieving MMR and 100% (10/10) maintaining MMR. Also Read: ...

Patients who achieved a major molecular response (MMR; BCR-ABL1 ≤0.1%) within 3 months had a 4-year progression-free survival (PFS) rate of about 80%, whereas those who did not meet that landmark ...

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety ...

(Reuters) - Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current ...

The MarketWatch News Department was not involved in the creation of this content. 64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy ...

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, ...

(MENAFN- GlobeNewsWire - Nasdaq) 64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging ...